Anti-CD20 therapy acts via FcγRIIIA to diminish responsiveness of human natural killer cells

Cancer Research

Volumn 75, Issue 19, 2015, Pages 4097-4108

  Capuano, Cristina ^a   Romanelli, Maddalena ^b   Pighi, Chiara ^b   Cimino, Giuseppe ^a,c   Rago, Angela ^c   Molfetta, Rosa ^b   Paolini, Rossella ^b   Santoni, Angela ^b   Galandrini, Ricciarda ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SANTA MARIA GORETTI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; GAMMA INTERFERON; LYMPHOCYTE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; OFATUMUMAB; PHOSPHOLIPASE C GAMMA; PROTEIN 2B4; PROTEIN DNAM 1; PROTEIN SLP 76; PROTEIN VAV1; RITUXIMAB; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MONOCLONAL ANTIBODY; OPSONIN; PHOSPHOPROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 1; PTPN6 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SLP-76 SIGNAL TRANSDUCING ADAPTOR PROTEINS; VAV PROTEIN; VAV1 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CELL INTERACTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CROSS TOLERANCE; CYTOKINE RELEASE; DENSITOMETRY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; HUMAN; HUMAN CELL; INTERNALIZATION; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL CULTURE; CELL GRANULE; DRUG EFFECTS; ENDOCYTOSIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING; SECRETION (PROCESS); TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; CELLS, CULTURED; CYTOPLASMIC GRANULES; ENDOCYTOSIS; GPI-LINKED PROTEINS; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA RELEASE TESTS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; OPSONIN PROTEINS; PHOSPHOLIPASE C GAMMA; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTO-ONCOGENE PROTEINS C-VAV; RECEPTORS, IGG; RITUXIMAB;

EID: 84945565968     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0781     Document Type: Article

References (47)

1. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010;95:135-43.
2. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and IImonoclonal antibodies. Semin Hematol 2010;47: 107-14.
3. Taylor RP, Lindorfer MA. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol Pharmacol 2014;86:485-91.
4. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-69.
5. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99: 754-58.
6. Stolz C, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009;50: 873-85.
7. Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol 2010;47:124-32.
8. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648-54.
9. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011;118: 3347-49.
10. Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, et al. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am J Hematol 2014;89: 757-65.
11. Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 2007;13:2392-99.
12. Trinchieri G, Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immunol 1993;12:218-34.
13. Lanier LL, Yu G, Phillips JH. Analysis of Fc gamma RIII (CD16) membrane expression and association with CD3 zeta and Fc epsilon RI-gamma by sitedirected mutation. J Immunol 1991;146:1571-76.
14. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013;31:227-58.
15. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008;9:495-502.
16. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-37.
17. Tripathy SK, Keyel PA, Yang L, Pingel JT, Cheng TP, Schneeberger A, et al. Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J Exp Med 2008;205:1829-41.
18. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010;115:1166-74.
19. Narni-Mancinelli E, Jaeger BN, Bernat C, Fenis A, Kung S, De Gassart A, et al. Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science 2012;335:344-8.
20. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56.
21. Capuano C, Paolini R, Molfetta R, Frati L, Santoni A, Galandrini R. PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway. Blood 2012;119:2252-62.
22. Tuccillo FM, Palmieri C, Fiume G, de Laurentiis A, Schiavone M, Falcone C, et al. Cancer-associated CD43 glycoforms as target of immunotherapy. Mol Cancer Ther 2014;13:752-62.
23. Castriconi R, Dondero A, Cantoni C, Della Chiesa M, Prato C, Nanni M, et al. Functional characterization of natural killer cells in type I leukocyte adhesion deficiency. Blood 2007;109:4873-81.
24. Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, et al. c-Cbl regulates MICA-but not ULBP2-inducedNKG2Ddown-modulation in human NK cells. Eur J Immunol 2014;44:2761-70.
25. Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013;121:3599-608.
26. Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood 2013;121:4694-702.
27. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008;8:713-25.
28. Galandrini R, Capuano C, Santoni A. Activation of lymphocyte cytolytic machinery: where are we? Front Immunol 2013;4:390.
29. Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 2012;122: 3769-80.
30. Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 2001;167:3391-97.
31. Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest 2013;123:1044-56.
32. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008;224:70-84.
33. Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, et al. Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat Immunol 2013;14:1127-36.
34. Cox MC, Battella S, LaScaleia R, Pelliccia S, Di Napoli A, Porzia A, et al. Tumor-associated and immunochemotherapy dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. Oncoimmunology 2015;4:e990773.
35. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014;124:2668-82.
36. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011;117:2423-32.
37. Deguine J, Breart B, Lemaître F, Bousso P. Cutting edge: tumortargeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions. J Immunol 2012;189: 5493-97.
38. Kim HS, Long EO. Complementary phosphorylation sites in the adaptor protein SLP-76 promote synergistic activation of natural killer cells. Sci Signal 2012;5:ra49.
39. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000;1:419-25.
40. Binstadt BA, Billadeau DD, Jevremović D, Williams BL, Fang N, Yi T, et al. SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors. J Biol Chem 1998;273:27518-23.
41. Stebbins CC, Watzl C, Billadeau DD, Leibson PJ, Burshtyn DN, Long EO. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 2003;23: 6291-99.
42. Pfirsch-Maisonnas S, Aloulou M, Xu T, Claver J, Kanamaru Y, Tiwari M, et al. Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci Signal 2011;4:ra24.
43. Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 2012;119:5758-68.
44. Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffié C, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005;22:31-42.
45. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E, et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. Blood 2012;119:3084-96.
46. Ben Mkaddem S, Hayem G, Jönsson F, Rossato E, Boedec E, Boussetta T, et al. Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J Clin Invest 2014;124:3945-59.
47. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187-98.